MedPath

SELZENTRY

These highlights do not include all the information needed to use SELZENTRY safely and effectively. See full prescribing information for SELZENTRY. SELZENTRY (maraviroc) TabletsInitial U.S. Approval: 2007

Approved
Approval ID

2b5e5c5d-852a-413b-825c-8491d4539e67

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

May 23, 2012

Manufacturers
FDA

Physicians Total Care, Inc.

DUNS: 194123980

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Maraviroc

PRODUCT DETAILS

NDC Product Code54868-5809
Application NumberNDA022128
Marketing CategoryC73594
Route of AdministrationORAL
Effective DateMay 23, 2012
Generic NameMaraviroc

INGREDIENTS (12)

MaravirocActive
Quantity: 300 mg in 1 1
Code: MD6P741W8A
Classification: ACTIB
cellulose, microcrystallineInactive
Code: OP1R32D61U
Classification: IACT
anhydrous dibasic calcium phosphateInactive
Code: L11K75P92J
Classification: IACT
sodium starch glycolate type A potatoInactive
Code: 5856J3G2A2
Classification: IACT
magnesium stearateInactive
Code: 70097M6I30
Classification: IACT
FD&C blue no. 2Inactive
Code: L06K8R7DQK
Classification: IACT
aluminum oxideInactive
Code: LMI26O6933
Classification: IACT
lecithin, soybeanInactive
Code: 1DI56QDM62
Classification: IACT
polyethylene glycolsInactive
Code: 3WJQ0SDW1A
Classification: IACT
polyvinyl alcoholInactive
Code: 532B59J990
Classification: IACT
talcInactive
Code: 7SEV7J4R1U
Classification: IACT
titanium dioxideInactive
Code: 15FIX9V2JP
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.